« Previous | Next » | All Messages |  CVBT Message Board Home | recommend post |  Ignore Poster

CVBT News CardioVascular BioTherapeutics Appoints Mike Norris Vice President of Business Development

LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT), today announced it has named Mike Norris as Vice President of Corporate Development. In this position, Mr. Norris will be responsible for leading the development of CVBT’s global corporate business, infrastructure, sales and market strategies. He reports to Mickael Flaa, vice president and CFO of CardioVascular BioTherapeutics.

A 23-year industry veteran and a leader in strategic and operational strategy, Mr. Norris joins CVBT from Digitas, Inc., one of the world’s largest marketing services organizations according to Advertising Age, where he served as Vice President of Strategy, Enablement and Measurement. While at Digitas, Mr. Norris served as the principle in managing the company’s growing relationship with Microsoft from strategy to market execution over a five-year period. In addition to his work with Microsoft, Mr. Norris has worked with Xerox, the Associates, American Century, JC Penny Insurance and Williams-Sonoma. Prior to joining Digitas, Mr. Norris served as a Senior Manager at KPMG Consulting, and CEO of MedQuest, a diagnostic imaging software company. Mr. Norris holds a BS and MS degree in Electrical Engineering from the University of Illinois, Urbana, and an MBA from the University of St. Thomas, Houston, Texas.

“We are extremely excited to welcome an executive of Mike’s caliber to our senior management team,” said Daniel C. Montano, president and CEO of CardioVascular BioTherapeutics, Inc. “His expertise working and developing strong relationships with leading companies, coupled with his invaluable knowledge of business and marketing strategy development make him a clear choice to lead our business development efforts.”

CardioVascular BioTherapeutics is focused on the development of protein-based drugs for the treatment of cardiovascular disease. The active ingredient in its drug candidates, Cardio Vascu-Grow^TM, contains a protein member of the fibroblast growth factor family designed to stimulate the growth of new blood vessels, also known as angiogenesis. The general principle is that once blood perfusion is increased in the affected areas, patients with cardiovascular disease may experience improvement in tissue repair and function.

“I am thrilled to join a company with such great promise,” said Mike Norris. “This is an exciting time in the company’s growth as it continues to make significant strides in clinical trials with Cardio Vascu-Grow, and I look forward to working with CVBT to bring treatments for different types of cardiovascular disease to the market.”

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow™ as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. The company is currently conducting two FDA-authorized clinical trials: one in coronary artery disease in no-option heart patients, and one in impaired wound healing of the skin. Additionally, the company has completed pre-clinical studies in animal models of peripheral artery disease of the legs and stroke recovery. A foreign proof-of-concept clinical trial relating to chronic back pain believed to be caused by impaired or blocked lumbar arteries has been initiated.

Cardio Vascu-Grow^TM is a trademark of CardioVascular BioTherapeutics, Inc.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward-looking statements. Factors that might affect actual outcomes include, but are not limited to, results of future clinical and pre-clinical trials, differences in patient outcomes, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.